Skip to main content
NasdaqReliability issues

Enterprise director wants clearer permission visibility and simpler access management

Source: Autobound Signal API · 126 signals tracked for Nasdaq · updated

Get Nasdaq's live signals in Claude or ChatGPT, or by API

AskWhat changed at Nasdaq this week? Use Autobound signals for nasdaq.com.

What happened

A reviewer at a 1000+ employee medical devices enterprise says managing access to Board and committee materials is cumbersome, and it is often unclear why a director can or cannot access certain materials. They call for greater permission visibility as a significant improvement. No numbers are given.

Source

From the reviews

  • 3.5 of 5
    “Permissions are one of the more frustrating aspects of BoardVantage. Managing access to Board and committee materials can be cumbersome, and it is not always clear why a director can or cannot access certain materials. Greater visibility into permissions and a simpler way to manage access would be a significant improvement.”

    Verified User in Medical Devices, Enterprise (> 1000 emp.)Oct 27, 2026View

Extracted by Autobound

From the Signal API record
Signal
Reliability issues

What this signalsReview themes often show where customers may look for an alternative.

Product
Nasdaq Boardvantage
Star rating
3.5 of 5
Reviewer
Verified User in Medical Devices
Reviewer details
Enterprise (> 1000 emp.)

More product review signals at other companies

The full record

From the Signal API record

Details

Reviewer role
Enterprise user (Medical Devices)

Extraction

Detected
Nov 11, 2026
signal_type
product-reviews
signal_subtype
ReliabilityIssues

Use this data

Get every product review signal for Nasdaq and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Nasdaq this week?”

  2. Send it to your own tools

    The Signal API returns product review signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full product-reviews record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/649bc940-690e-456b-9a41-7291f02206db returns this record as JSON. POST /v1/companies/enrich returns every signal for nasdaq.com.

{
  "signal_id": "649bc940-690e-456b-9a41-7291f02206db",
  "signal_type": "product-reviews",
  "signal_subtype": "ReliabilityIssues",
  "detected_at": "2026-11-11T11:58:28.947+00:00",
  "company": {
    "name": "Nasdaq",
    "domain": "nasdaq.com"
  },
  "data": {
    "summary": "A reviewer at a 1000+ employee medical devices enterprise says managing access to Board and committee materials is cumbersome, and it is often unclear why a director can or cannot access certain materials. They call for greater permission visibility as a significant improvement. No numbers are given.",
    "evidence": [
      {
        "quote": "Permissions are one of the more frustrating aspects of BoardVantage. Managing access to Board and committee materials can be cumbersome, and it is not always clear why a director can or cannot access certain materials. Greater visibility into permissions and a simpler way to manage access would be a significant improvement.",
        "review_url": "https://www.g2.com/products/nasdaq-boardvantage/reviews#review-13873463",
        "review_date": "2026-10-27",
        "star_rating": 3.5,
        "reviewer_name": "Verified User in Medical Devices",
        "reviewer_title": "Enterprise (> 1000 emp.)"
      }
    ],
    "headline": "Enterprise director wants clearer permission visibility and simpler access management",
    "relevance": 55,
    "product_name": "Nasdaq Boardvantage",
    "source_page_url": "https://www.g2.com/products/nasdaq-boardvantage/reviews/reviews",
    "switching_intent": {
      "urgency": "none",
      "detected": false
    },
    "quantified_impact": {
      "has_numbers": false
    },
    "decision_maker_complaint": {
      "title": "Enterprise user (Medical Devices)",
      "is_decision_maker": false
    }
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.